NaviFUS is a pioneering Biotech company specializing in Focused Ultrasound technology. Our vision is to revolutionize oncology drug delivery by developing novel platform solutions for crossing the blood-brain barrier (BBB). Our flagship product, the NaviFUS System, utilizes non-invasive ultrasound energy to enhance BBB permeability, allowing for precise transportation of CNS drugs to target tumor tissue. By partnering with global pharmaceutical companies, we aim to benefit patients with CNS diseases worldwide.

Founded in 2015 by Dr. Hao-Li Liu, NaviFUS has quickly emerged as a leader in the field. Our management team comprises experienced individuals with extensive backgrounds in drug discovery, medical device development, and entrepreneurship. We prioritize collaboration, working together with our partners, customers, and peers to achieve success. Our commitment to innovation drives us to continuously seek newer and better ways to understand complex diseases and develop innovative treatment solutions.

With multiple successful clinical trials, including those for brain tumors and epilepsy, NaviFUS has garnered recognition and awards for our contributions to the medical field. Backed by over 30 patents and operating in more than 37 countries, we are committed to delivering cutting-edge therapeutic ultrasound technology for the benefit of patients globally.